Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verastem Inc VSTM

Healthcare Biotechnology
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more

Recent & Breaking News (NDAQ:VSTM)

Verastem Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2019

Verastem Oncology Added to the NASDAQ Biotechnology Index®

Business Wire December 20, 2018

Verastem Oncology Announces First Recipient of the Care Differently Award for Excellence in Patient Support and Education

Business Wire December 19, 2018

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 5, 2018

Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting

Business Wire December 4, 2018

Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting

Business Wire December 3, 2018

New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire December 3, 2018

Verastem Oncology Reports Third Quarter 2018 Financial Results

Business Wire November 7, 2018

Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma

Business Wire November 7, 2018

Verastem Oncology Announces Presentation of Preclinical Data Supporting Dual PI3K-delta and PI3K-gamma Inhibition in Combination with Immunotherapy at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Business Wire November 6, 2018

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 5, 2018

Verastem Oncology Announces Data Presentations at the American Society of Hematology 2018 Annual Meeting

Business Wire November 1, 2018

Verastem Oncology Announces Executive Leadership Appointments and Changes

Business Wire October 18, 2018

Verastem Oncology Announces Pricing of Registered Direct Offering of $150 Million of Convertible Notes

Business Wire October 11, 2018

National Comprehensive Cancer Network® Adds Verastem Oncology’s COPIKTRA™ (duvelisib) Capsules to Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Business Wire October 9, 2018

National Comprehensive Cancer Network® Adds Verastem Oncology’s COPIKTRA™ (duvelisib) Capsules to Clinical Practice Guidelines in Oncology

Business Wire October 8, 2018

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 5, 2018

Verastem Oncology Announces Publication of the Phase 3 DUO Study Results in the Journal Blood

Business Wire October 4, 2018

Verastem Oncology to Present at Upcoming Investor Conferences

Business Wire September 27, 2018

Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Benzinga.com  September 26, 2018